

Optum pharma ltd

Reg: 771842

Financial Statement :03/12/2025 to 12/03/2026 B1 Return

1. Date

This financial statement is prepared for the reporting period covering march 2025 to march 2026. The period aligns with the fiscal year requirements for the annual B1 return submission to the Companies Registration Office (CRO) of Ireland. All figures and accounts presented herein are accurate for this specific twelve-month duration.

The statement serves as the official financial record for Optum Pharma Ltd for the year ending march 2026. It is prepared in accordance with the timelines stipulated by the Companies Act 2014 for the filing of annual returns, ensuring compliance with statutory deadlines for the period between 12/03/2025 and 12/03/2026.

2. Opening / Context

This document constitutes the complete set of financial statements for Optum Pharma Ltd, prepared for the purpose of submission with the annual B1 return to the Companies Registration Office (CRO) of Ireland. The statements have been compiled to present a true and fair view of the company's financial performance and position for the year ended march 2026.

The preparation of these statements is in compliance with the relevant provisions of the Irish Companies Act 2014, which governs the filing requirements for all registered companies. The information provided forms an integral part of the company's statutory reporting obligations for the stated period and is to be filed to maintain the company's legal standing.

3. Profit and Loss Statement

The Profit and Loss Statement for the period summarizes the company's financial performance. It details all income generated and expenses incurred during the operational year, culminating in the net result for the period.

The statement clearly shows the financial outcome of the company's activities, which is essential for assessing operational efficiency and financial health over the reporting period. The figures reflect the strategic decisions made during this foundational phase of the company's development.

Description	Amount (EUR)
Total Revenue	0
Operating Expenses	
Rent	4,000
Salaries	6,000
IT and Infrastructure	3,000
CPHI Frankfurt (Marketing/Networking)	5,000
Total Operating Expenses	18,000
Net Loss	-18,000

4. Balance Sheet

The Balance Sheet presents a snapshot of the company's financial position at the close of the reporting period. It outlines the company's assets, liabilities, and equity, providing insight into its net worth and financial stability at that specific date.

This statement is fundamental for understanding what the company owns and owes, reflecting the cumulative financial impact of all transactions and the result from the Profit and Loss statement. The position at year-end indicates the state of the company following its initial investment phase.

Balance Sheet Category	Value (EUR)
Total Assets	0
Total Liabilities	0
Net Cash Flow	0

5. Position / Key Message

The financial results for the year indicate a period of strategic investment and development for Optum Pharma Ltd, with no revenue generated during this initial phase. The company has incurred necessary operating expenses to establish its core infrastructure and market presence, resulting in a net loss for the period.

This net loss of 18,000 EUR is a direct result of strategic expenditures in key operational areas, including personnel, technology, and business development, which are foundational for future growth. The balance sheet reflects a position where total assets and total liabilities are both nil, with no closing cash balance carried forward, as all funds were utilized for operational setup.

6. Supporting Points

The total operating expenses of 18,000 EUR are comprised of several critical cost centres essential for business operations. These expenses represent the company's commitment to establishing a functional and professional foundation from which to launch its commercial activities in the pharmaceutical sector.

A detailed review of the expense categories confirms their necessity and alignment with the company's operational plan for the year. Each category contributed to maintaining the company's legal standing, operational capability, and market outreach efforts during the reporting period.

Rent & Salaries

The rent expense of 4,000 EUR covers the cost of premises necessary for administrative and operational functions, ensuring a professional business address and workspace. The salaries expense of 6,000 EUR represents compensation for managerial and administrative personnel essential for day-to-day operations, corporate governance, and strategic planning during the setup phase.

IT & Marketing

The IT and Infrastructure cost of 3,000 EUR was incurred for essential technology, software licenses, communication systems, and cybersecurity measures required for a modern pharmaceutical business. The CPHI Frankfurt expenditure of 5,000 EUR was a strategic marketing and networking investment aimed at critical industry engagement, brand visibility, and future business development at a premier global pharmaceutical event.

7. Call to Action or Resolution

It is hereby resolved that these financial statements, comprising the Profit and Loss Statement for the period and the Balance Sheet as of March 2026, be formally approved for submission. They are to be filed as an integral component of the company's yearly B1 return with the Companies Registration Office (CRO) of Ireland for the period between 12/03/2025 and 12/03/2026.

The directors confirm that these statements accurately reflect the company's financial activities and position for the stated period and have been prepared in accordance with the Irish Companies Act 2014. Timely filing of this return is imperative to maintain the company's good standing and compliance with Irish company law.